Tatva Chintan Pharma Chem Limited — PPTs, 31-10-2025: Investor Presentation

Tatva Chintan Pharma Chem delivered robust consolidated Q2 FY26 results. Revenue surged 48% year-on-year to ₹123.5 Cr, with Profit After Tax (PAT) dramatically increasing to ₹9.9 Cr from a previous loss. For H1 FY26, revenue grew 27% year-on-year to ₹240.4 Cr, and PAT climbed 265% to ₹16.6 Cr. Earnings per share also saw strong improvement. Growth was notably strong in Structure Directing Agents (SDA), accounting for 48% of Q2 revenue.

The company's strategy emphasizes green chemistry processes like electrolysis for SDA production and developing continuous flow chemistry, backed by significant R&D investment. Recent developments include the commencement of commercial production at its expanded Dahej SEZ facility and raising ₹200 Cr through a Qualified Institutional Placement in August 2023 to boost capacities.

Tatva Chintan maintains a strong position in niche specialty chemicals, benefiting from India's expanding footprint in the global chemical market, the 'China+1' strategy, and a growing demand for sustainable products. Their diversified product portfolio, technical expertise, and high industry entry barriers are key strengths driving future growth.